AC Immune Aktie
| 3,09USD | -0,23USD | -6,93% |
WKN DE: A2AR5F / ISIN: CH0329023102
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 143 | 156 | 161 | 172 | 122 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,03 | 0,10 | 0,18 | 0,04 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 222 | 138 | 149 | 190 | 122 |
| Summe Anlagevermögen | 65 | 63 | 69 | 65 | 73 |
| Summe Aktiva | 287 | 201 | 217 | 255 | 195 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 32 | 18 | 26 | 131 | 138 |
| Summe Eigenkapital | 255 | 183 | 191 | 124 | 57 |
| Summe Passiva | 287 | 201 | 217 | 255 | 195 |
Adresse
| EPFL Innovation Park, 1015 Lausanne | |
| Telefon | +41 (21) 345-91-21 |
| Internet | http://www.acimmune.com |
Management
|
Andrea Pfeifer
Chief Executive Officer |
|
Bojana Portmann
VP-Intellectual Property & Business Development |
|
Christopher Roberts
Chief Financial Officer & Vice President |
|
Gary Waanders
Head-Investor Relations & Corporate Communications |
|
Julien Rongère
VP-Regulatory Affairs & Quality Assurance |
|
Mark Danton
VP-Information Systems & Security |
|
Martin Zügel
Chairman |
|
Matthias Maurer
Senior Vice President-General Counsel |
|
Monika Bütler
Vice Chairman |
|
Oliver Sol
VP & Head-Clinical Development |
|
Piergiorgio Donati
Chief Technical Operations Officer |
|
Renée Julie Elisabet Aguiar-Lucander
Director |
|
Roy Ervin Twyman
Independent Non-Executive Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.